CHANGES IN HUMORAL IMMUNITY INDICATORS IN WOMEN WITH CERVICAL DYSPLASTIC PROCESS
Keywords:
immunoglobulinAbstract
Research results show that the prevention of tumor diseases, their early diagnosis, and uncomplicated treatment are of great importance. However, one of the most serious problems in these pathologies is their primary detection. One of the systems sensitive to pre-pathological conditions in the body is the immune system, whose cellular and humoral factors react with quantitative and qualitative changes to the ongoing pre-pathological states in the body, which occur asymptomatically and without external clinical manifestations. It has been shown that quantitative changes in these factors indicate pre-disease states of the body.
References
1. Abakumova T.V., Myagdieva I.R., Dolgova D.R., Gening S.O., Antoneeva I.I., Gening T.P. IL-4 and its polymorphism (IL4-589C/T) in cervical neoplasia // Medical Immunology. -- 2023. -- Vol.25, No.5. -- P.1129-1134.
2. Belyavskaya V.A., Cherdyntseva N.V., Kzhyshkovskaya Yu.G., Litvyakov N.V. Microbiome, immune system and cancer: three sides of one medal // Siberian Journal of Oncology. -- 2022. -- No.21(6). -- P.131-144.
3. Gizinger O.A. Immunomodulation in gynecology. Opinion of an immunologist and obstetrician-gynecologist. Questions of practical colposcopy // Genital Infections. -- 2022. -- No.2. -- P.18-23.
4. Ikhtiyarova G.A., Navruzova N.O., Karimova G.K. Modern diagnostic methods for early detection of cervical diseases // Doctor Akborotnomasi. -- 2019. -- No.4. -- P.78-80.
5. Loginova O.P., Shevchenko N.I., Gasich E.L. Features of local vaginal immunity in HPV-negative cervical dysplasia // News of Medical and Biological Sciences. -- 2025. -- Vol.25, No.3. -- P.230-239.
6. Mazitova M.I., Bikineev M.S. Stages of development of cytological screening for cervical cancer // RMJ. Mother and Child. -- 2019. -- Vol.2, No.4. -- P.322-326.
7. Mamedov U.S., Mirakhamedova S.S. Dynamics of immune status of women during treatment of human papillomavirus of the cervix // Bulletin of Science and Education. -- 2020. -- No.24(102), Part 3. -- P.81-84.
8. Petrov Yu.A., Blesmanovich A.E., Bagnovskaya A.G. From background processes to cervical cancer: causes, diagnosis and prevention // Chief Physician of the South of Russia. -- 2020. -- Vol.74, No.4. -- P.36-39.
9. Semiglazov V.F. et al. Immunology and immunotherapy in the complex treatment of malignant tumors // Medical Council. -- 2021. -- No.4. -- P.248-257.
10. Mamedov U.S., Pulatova D.SH. The Results of Cancer Treatment of the Oral Cavity Tumors in The Republic of Uzbekistan // European Journal of Pharmaceutical and Medical Research. -- 2019. -- V.6, N9. -- P.326-329.
11. Oripova F.Sh., Ikhtiyarova G.A., Davlatov S.S. Pathomorphological characteristics of the vaginal mucosa in experimental nonspecific vaginitis and various methods of treatment // International Journal of Pharmaceutical Research. -- 2021. -- V.13, N1. -- P.761-765.
12. Smola S., Trimble C., Stern P.L. Human papillomavirus-driven immune deviation: challenge and novel opportunity for immunotherapy // Ther Adv Vaccines. -- 2017. -- V.5. -- P.69-82.
13. Wang Y., Li G. PD-1/PD-L1 blockade in cervical cancer: current studies and perspectives // Front Med. -- 2019. -- V.13. -- P.438-450.
14. Zhen S. et al. Synergistic antitumor effect on cervical cancer by rational combination of PD1 blockade and CRISPR-Cas9-mediated HPV knockout // Cancer Gene Ther. -- 2019. -- V.27. -- P.168-178.
